Entry into the cancer immunotherapy and blockchain businesses through an investment in RIRM
First written in FY2019-Q2. 1 of 2 entries say "Dropped", first in FY2019-Q3. Latest entry: FY2019-Q3.
No other company in this theme has enough history to compare yet.
- FY2019-Q3DroppedAnnual report
「At a meeting of the Board of Directors held on 14 February 2019, the company resolved that its wholly owned subsidiary SUN GREEN POWER ENERGY PTE.LTD. (hereinafter, “SGPE”) would transfer all shares of RIKEN IMMUNE REGENERATIVE MEDICINE PTE.LTD. (hereinafter, “RIRM”), which it owns, to ORCHID PARTNERS PTE.LTD. for S$3,750,000, and SGPE executed a share transfer agreement on the same date. The share transfer had no impact on profit or loss. Following the share transfer, RIRM is no longer included in the scope of consolidation as a subsidiary held temporarily.」
Regarding RIRM, for which a resolution to make it a subsidiary was passed in the previous quarter, a resolution was passed to transfer all its shares for S$3,750,000, and a share transfer agreement was executed. Entry into the cancer immunotherapy and blockchain businesses through RIRM is expected to end as a result of the sale. - FY2019-Q2First statedAnnual report
「At a meeting of the Board of Directors held on 16 October 2018, the Company resolved that its wholly owned subsidiary, SUN GREEN POWER ENEGY PTE. LTD., would acquire shares in RIKEN IMMUNE REGENERATIVE MEDICINE PTE. LTD. (hereinafter, “RIRM”) and make it a subsidiary. On the same day, SUN GREEN POWER ENEGY PTE. LTD. entered into a share transfer agreement with ORCHID PARTNERS PTE. LTD.」
A resolution was passed to acquire RIRM's shares and make it a subsidiary, and a share transfer agreement was executed. The voting rights to be acquired represent 66.67%, with the objectives of providing cancer immunotherapy technology targeting NKT cells and entering the platform business utilizing blockchain technology.